#United States #Los Angeles #Schall Law Firm #Securities Fraud #BioAge Labs

Overview of the Legal Action

In a significant move for investors, the Schall Law Firm has filed a class action lawsuit against BioAge Labs, Inc., a biopharmaceutical company listed on NASDAQ under the symbol BIOA. The lawsuit focuses on alleged violations of federal securities laws, particularly concerning misleading information that may have impacted investors' decisions.

Background on BioAge Labs

Established to harness human biology to develop therapies that address age-related diseases, BioAge Labs recently faced scrutiny following its initial public offering (IPO) on September 26, 2024. Investors who acquired shares at this time are being invited to join the legal action, particularly if they experienced financial losses tied to the company's subsequent performance.

The Allegations

According to the filed complaint, BioAge Labs misrepresented critical information during its IPO that inaccurately portrayed the safety and efficacy of its lead therapy candidate, azelaprag. On December 6, 2024, the company disclosed its decision to halt the ongoing Phase 2 clinical trial for azelaprag, citing safety concerns. This was in stark contrast to prior statements made during the IPO where the company asserted the drug's potential benefits for patients engaging with obesity therapies involving incretin drugs. The lawsuit contends that these misleading statements led to significant losses for investors once the true situation was revealed.

Joining the Class Action

Investors who purchased BioAge's securities at or after the IPO are encouraged to reach out to the Schall Law Firm before the deadline of March 10, 2025. Participation in the class can potentially lead to recovering some of the financial damages incurred. Brian Schall, the attorney leading this case, has clarified that until the class is certified, those who do not take action will remain as absent class members and may relinquish their right to recover losses.

Contact Information for Interested Parties

For those interested in joining the lawsuit or seeking more information, contacting the Schall Law Firm directly is essential. Brian Schall can be reached at 310-301-3335 or through the firm's website at www.schallfirm.com. By engaging with the firm, investors can discuss their rights and the specifics of the legal action at no cost.

Conclusion

This legal pursuit illustrates the challenging landscape that investors navigate in the biotech arena, where clinical successes and failures are deeply intertwined with market perceptions and stock performance. The Schall Law Firm's proactive approach underscores its commitment to safeguarding investor rights and ensuring accountability among public companies. Investors are urged to act swiftly to protect their interests in this unfolding situation.